New drug combo challenges standard treatment for advanced breast cancer
NCT ID NCT06057610
Summary
This large Phase 3 trial is testing whether a new drug called SHR-A1811, given with or without another medication, works better than the current standard treatment for advanced HER2-positive breast cancer that has returned or spread. The study will enroll 868 women to compare how long patients live without their cancer getting worse and monitor side effects. The goal is to find more effective ways to control this aggressive form of breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVERECURRENT OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.